A study published in the journal Cell marks the first reported instance of generative AI designing synthetic molecules that ...

When examining artificial intelligence in healthcare, Eric Cheng, MD, CMIO of UCLA Health Sciences, takes a systemic, data-driven approach. In a recent interview on the “Becker’s Healthcare Podcast,” ...

1910 Genetics' platform differs from other players because its AI and computational platforms – ELVIS for small molecules and ROSALYND for proteins – is driven by biological properties like ...

Q1 2025 Management View CEO Sam Raha opened the call by highlighting a challenging Q1 2025, with revenue of $196 million, ...

Colossal Biosciences' claim to have achieved the 'de-extinction' of the dire wolf has been questioned by geneticists, but the ...

A new liquid biopsy approach developed by Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer ...

Predictive analytics systems now analyze patient genetics and lifestyle data to detect diseases before symptoms appear, enabling earlier interventions and signi ...

Worldwide, The development of hormone-free In Vitro Fertilisation, direct-thaw frozen embryo programs and greatly improved ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Tempus AI has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca and ...

Stocks recently featured in the blog include: Tempus AI TEM, AstraZeneca AZN, iRhythm Technologies IRTC and SOPHiA GENETICS SOPH. Here are highlights from Thursday’s Analyst Blog: Tempus AI ...